<DOC>
	<DOCNO>NCT00405925</DOCNO>
	<brief_summary>Antiretroviral na誰ve patient &lt; 350 xE6/l CD4 cell HIV-viral load &gt; 30.000 cop/ml start combivir 速 Kaletra 速 . When patient reach undetectable viral load &lt; 50 cop/ml two consecutive occasion least week 12 , later week 24 , randomise either continuation Combivir/Kaletra switch Trizivir 速 twice daily one pill 96 week . All patient randomise combivir/Kaletra arm eligible switch Trizivir post randomisation visit reach predefined switch criterion elevate level fast glucose lipid .</brief_summary>
	<brief_title>FREE Study : Efficacy Toxicity Trizivir</brief_title>
	<detailed_description>The primary objective compare antiviral efficacy early switch boost PI/2NRTI regimen Trizivir ( undetectability HIV-RNA achieve 2 consecutive occasion ) uninterrupted use PI/2NRTI regimen 96 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Adults &gt; 18 year age , confirm HIV1 infection , never receive antiretrovirals , plasmaHIVRNA &gt; 30.000 cop/ml , CD4 &lt; 350 E6/l . pregnancy , woman use proven barrier method contraception , define uncontrolled active AIDS defining complication , treatment diabetes , serious illness , expect noncompliance , define laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>AIDS</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>